动脉瘤性蛛网膜下腔出血的生物标志物差异:伴与不伴迟发性脑缺血患者的比较研究
本研究为前瞻性纵向研究,纳入86例动脉瘤性蛛网膜下腔出血患者,其中28例发生迟发性脑缺血。探索性分析按年龄、性别和严重程度评分匹配8例迟发性脑缺血患者与8例无迟发性脑缺血对照,采用Olink Explore 3072平台检测2,943种血浆蛋白。线性贝叶斯模型经错误发现率校正后,鉴定出15种显著失调蛋白(P < 0.01),包括下调的THSD1、CA3、PROK1(与血管完整性和内皮功能相关)及上调的BGN、IFNG、CSF2(与先天免疫和神经炎症相关),新候选蛋白CLSTN3和DOCK9表达亦改变。蛋白互作与基因本体富集分析提示炎症、免疫和代谢通路参与。作者认为这些候选标志物需在更大队列中进一步验证,其潜在临床价值需独立研究确认。
要点
- 在86例动脉瘤性蛛网膜下腔出血患者中,28例发生迟发性脑缺血,探索性分析匹配8例迟发性脑缺血与8例对照。
- 入住ICU 24小时内血浆蛋白组学鉴定出15种显著失调蛋白(P < 0.01),涉及血管完整性、内皮功能、先天免疫和神经炎症。
- 下调蛋白包括THSD1、CA3、PROK1;上调蛋白包括BGN、IFNG、CSF2;新候选蛋白CLSTN3和DOCK9表达亦改变。
- 作者认为这些候选生物标志物需在更大队列中进一步验证,其潜在临床价值需独立研究确认。
适用人群与场景
- 动脉瘤性蛛网膜下腔出血患者,纳入86例,其中28例发生迟发性脑缺血。
- 探索性分析匹配8例发生迟发性脑缺血患者与8例无迟发性脑缺血对照,匹配因素为年龄、性别和严重程度评分。
研究设计与关键结果
- 研究类型为前瞻性纵向研究,纳入86例动脉瘤性蛛网膜下腔出血患者,其中28例发生迟发性脑缺血。
- 探索性分析匹配8例迟发性脑缺血患者与8例无迟发性脑缺血对照,基于年龄、性别和严重程度评分匹配。
- 采用Olink Explore 3072平台检测2,943种血浆蛋白,线性贝叶斯模型经错误发现率校正。
- 鉴定出15种显著失调蛋白(P < 0.01):下调蛋白包括THSD1、CA3、PROK1(与血管完整性和内皮功能相关);上调蛋白包括BGN、IFNG、CSF2(与先天免疫和神经炎症相关);新候选蛋白CLSTN3和DOCK9表达亦改变。
- 蛋白互作和基因本体富集分析显示涉及炎症、免疫和代谢通路。
证据类型、等级与局限
- 证据类型:前瞻性纵向研究的探索性分析。
- 作者指出这些候选生物标志物需在更大队列中进一步验证,其潜在临床价值需独立研究确认。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些候选生物标志物可能为迟发性脑缺血的生物学过程提供初步见解,但需在更大队列中进一步验证,其潜在临床价值需独立研究确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Delayed cerebral ischemia (DCI) is a major cause of morbidity following aneurysmal subarachnoid hemorrhage (aSAH), yet early prediction remains challenging. This study aimed to identify blood-based protein biomarkers within 24 h of intensive care unit admission associated with DCI using high-throughput proteomics.
METHODS: We conducted a prospective longitudinal study including 86 patients with aSAH, of whom 28 developed DCI. For this exploratory analysis, we matched eight patients who developed DCI with eight controls without DCI based on age, sex, and severity scores. Plasma samples were analyzed using the Olink Explore 3072 platform targeting 2,943 proteins. Differential expression analysis was performed using linear Bayesian models with false discovery rate correction.
RESULTS: We identified 15 significantly dysregulated proteins (P < 0.01) in patients with DCI. Key downregulated proteins included THSD1, CA3, and PROK1, which are associated with vascular integrity and endothelial function. Upregulated proteins included BGN, IFNG, and CSF2, which are related to innate immunity and neuroinflammation. Novel candidates, such as CLSTN3 and DOCK9, also showed altered expression. Protein-protein interaction and gene ontology enrichment analyses revealed involvement in inflammatory, immune, and metabolic pathways.
CONCLUSIONS: Our findings suggest a distinct early molecular signature in patients with aSAH who develop DCI, characterized by proinflammatory and neurovascular dysfunction markers. These candidate biomarkers warrant further validation in larger cohorts and may provide preliminary insight into biological processes associated with DCI. Their potential clinical value will require confirmation in independent studies.
参考来源
- Santafé M, Quintana M, Sánchez A, et al. Biomarker Differences in Aneurysmal Subarachnoid Hemorrhage: A Comparative Study of Patients with and Without Delayed CEREBRAL Ischemia. Neurocrit Care. 2025. PMID: 41266703. doi:10.1007/s12028-025-02410-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。